Literature DB >> 11867687

Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.

Maria Teresa de la Fuente1, Benito Casanova, José V Moyano, Mercedes Garcia-Gila, Laura Sanz, José Garcia-Marco, Augusto Silva, Angeles Garcia-Pardo.   

Abstract

B-cell chronic lymphocytic leukemia is characterized by the accumulation of malignant B lymphocytes as a result of abnormal survival signals operating in vivo. Previously, we showed that adhesion of B-CLL cells to the fibronectin fragment H89, a ligand for alpha4beta1 integrin, prevents their spontaneous apoptosis in vitro. We have now studied whether alpha4beta1/H89 interaction affected the response of B-CLL cells to the therapeutic drug fludarabine. B-CLL cells cultured on H89 during treatment with fludarabine showed significantly higher mean viability (P<0.05) than cells cultured on the control polylysine for all doses of drug tested. Similar results were obtained with the EHEB cell line. Analysis of the expression of Bcl-2-family proteins after 48 h of fludarabine treatment revealed that Bcl-xL levels were significantly higher (P<0.05) for cells cultured on H89 than on polylysine and correlated (r=0.56, P<0.05) with the increased cell viability observed on H89 cultures. These results indicate that Bcl-xL is involved in the survival signals induced by alpha4beta1 ligation and may contribute to the progressive drug resistance observed in B-CLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867687

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  29 in total

1.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

2.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

3.  The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance.

Authors:  Chi-Chao Liu; Pascal Leclair; Shyong Quin Yap; Chinten James Lim
Journal:  Mol Cell Biol       Date:  2013-09-03       Impact factor: 4.272

4.  Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA) Requires Death Receptor Fas, in Addition to LFA-1, To Trigger Cell Death in T Lymphocytes.

Authors:  Brian A Vega; Liam T Schober; Tami Kim; Benjamin A Belinka; Scott C Kachlany
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

5.  α4β1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling.

Authors:  Alejandra Gutiérrez-González; Noemí Aguilera-Montilla; Estefanía Ugarte-Berzal; Elvira Bailón; Isabel Cerro-Pardo; Clara Sánchez-Maroto; Lara García-Campillo; José A García-Marco; Angeles García-Pardo
Journal:  Blood Adv       Date:  2019-07-23

6.  A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Juan Pablo Albar; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

7.  LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes.

Authors:  Kristina M DiFranco; Nadine Johnson-Farley; Joseph R Bertino; David Elson; Brian A Vega; Benjamin A Belinka; Scott C Kachlany
Journal:  Leuk Res       Date:  2015-03-21       Impact factor: 3.156

Review 8.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

9.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

Review 10.  Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.

Authors:  Michele Dal-Bo; Francesco Bertoni; Francesco Forconi; Antonella Zucchetto; Riccardo Bomben; Roberto Marasca; Silvia Deaglio; Luca Laurenti; Dimitar G Efremov; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2009-08-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.